New ways to prevent urinary tract infections
Official title: Investigating Novel Methods to Combat Urinary Tract Infections
Funded at University of Washington · NIH-10705027 · Data updated 2026-11-12
This study is looking for new ways to treat urinary tract infections caused by tough bacteria, and it’s for anyone who has struggled with these infections; researchers are testing a special antibody that might stop the bacteria from sticking to the urinary tract, helping to create better treatments.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 16, 2022 |
| Project end | September 15, 2025 |
| Funding year | 2023 |
| Award (this year) | $125,000 |
| NIH project number | 5K99GM141364-02 |
| Project ID | NIH-10705027 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children, the elderly, diabetics, and immunocompromised individuals who are at higher risk for recurrent urinary tract infections.
✕Less likely to help
Patients who do not suffer from urinary tract infections or those with infections caused by non-target bacteria may not benefit from this research.
What this research studies
This research focuses on developing innovative treatments for urinary tract infections (UTIs), particularly those caused by drug-resistant bacteria like Klebsiella pneumoniae. The approach involves creating anti-adhesive molecules that prevent bacteria from attaching to the cells in the urinary tract, which is a critical step in infection. The study will explore the mechanism of action of a specific monoclonal antibody that has shown promise in blocking bacterial adhesion. By understanding how this antibody works, researchers aim to design new therapies that can effectively combat UTIs.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce the incidence and severity of urinary tract infections, especially in patients with limited treatment options.
How similar studies have gone: Previous research has shown promise in using monoclonal antibodies to inhibit bacterial adhesion, indicating that this approach has potential for success.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Magala, Pearl — University of Washington
- Study coordinator: Magala, Pearl
Related research
Other NIH-funded projects on the same topics.
-
New ways to stop urinary tract infections by blocking bacterial adhesion
A study to test new methods that prevent bacteria from sticking to urinary tract tissues and devices, potentially stopping infections before they start.
-
Hybridization capture sequencing to quickly identify canine urinary pathogens and resistance genes
A new sequencing approach directly from dog urine aims to rapidly identify bacteria causing urinary infections and their drug-resistance profiles to guide treatment.
-
Enterococcal Proteases and CAUTI: How the body’s environment activates bacteria to cause infections
A small grant is exploring how two enzymes from Enterococcus faecalis interact with the urine environment to drive catheter-associated urinary tract infections and why these infections are hard to treat.
-
Daily nitrofurantoin with or without bladder cauterization to prevent recurrent bladder infections in women
This study tests two approaches to prevent recurrent bladder infections in women: taking a low-dose antibiotic every day versus adding a bladder cauterization procedure plus the same daily antibiotic.
-
New bacterial pathway that helps cause bladder infections
Researchers are exploring how bacteria steal nutrients in the bladder and how the body fights them to help people with urinary tract infections.
-
New oral antifungal for tough Candida UTIs
A Johns Hopkins team is testing a new oral antifungal medicine called fungerps to treat urinary tract infections caused by azole-resistant Candida fungi.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.